Markets
FED Hearing July 10
Federal Reserve Chairman Jerome Powell testifies during the House Financial Services Committee hearing (Tom Williams/CQ-Roll Call, Inc via Getty Images)
jobs jobs jobs

Your full-time job is now Jay Powell's full-time job

Keeping the labor market from softening any further is the top US central banker’s top concern.

Luke Kawa

Two Federal Reserve officials laid out wildly competing visions for the US job market in the mountains of Wyoming over the past two days. 

And we should probably be glad that the more pro-labor view is coming from the person who’s ultimately in charge.

On Thursday, Philadelphia Fed chief Patrick Harker advocated for a “slow, methodical approach” to lowering interest rates and suggested that the unemployment rate would likely rise to close to 5%.

The cycle low for the unemployment rate is 3.4%; near 5% would mean a 1.5 percentage point increase in joblessness. Based on data going back to the late 1940s, every time the unemployment rate has gone up that much, the economy had either entered a recession or was about to do so. 

Neil Dutta, head of US economics at Renaissance Macro Research, flagged that based on a popular model that sketches out a relationship between joblessness and growth, reaching a 5% unemployment rate in a year’s time would imply that the economy contracted slightly. 

Harker is the bear case for the labor market, the economy, and by extension, the stock market, too. More joblessness equals less spending, which means lower corporate profits.

Fed Chair Jay Powell provided a stark contrast in his address at the Jackson Hole Economic Symposium on Friday morning.

While Harker seems to think that maintaining current labor market conditions isn’t a top priority, Powell’s speech included many forceful arguments that the central bank should want the labor market to be at least this good, if not better.

Some key quotes:

“...labor market conditions are now less tight than just before the pandemic in 2019—a year when inflation ran below 2 percent.”

Translation: We’ve had a better job market than this at a time when we weren’t worried about inflation, so we have room for labor market conditions to improve from here without fearing a long-lived resurgence in price pressures.

“We do not seek or welcome further cooling in labor market conditions.”

Translation: Well, I’m certainly not saying the unemployment rate should go to 5%!

“We will do everything we can to support a strong labor market as we make further progress toward price stability.”

Translation: a rising unemployment rate is currently more of a worry than inflation that is still a little higher than the central bank would prefer.

If Harker is the bear case, then Jay Powell is the bull case. And since he’s the one with the most influence among monetary decision-makers, investors are treating his bull case like it’s their base case – at least for today.

More Markets

See all Markets
markets

Trump administration says tariffs on Chinese semiconductor imports are coming... in 2027

After a year-long investigation into China’s tactics to bolster its domestic semiconductor industry, the US has determined that its practices are “unreasonable” and is going to do something about that in 18 months.

The Trump administration’s office of the US trade representative said today that it plans to impose tariffs on imports of Chinese semiconductors at a rate higher than 0% to be decided at least 30 days before June 23, 2027.

“China’s pursuit of its dominance goals has severely disadvantaged US companies, workers, and the U.S. economy generally through lessened competition and commercial opportunities and through the creation of economic security risks from dependencies and vulnerabilities,” per the USTR’s notice of action.

These levies, should they come to pass, would apply to silicon, diodes, transistors, and more.

US markets were completely unbothered by this revelation, likely because there is no immediate action against Chinese semi companies and therefore no disruption to business-as-usual. This represents a punting of a contentious matter, similar to how China delayed restrictions on rare earth shipments as part of a deal between Presidents Trump and Xi following their October meeting.

It’s another sign of a thaw in the US-China relations over the hot-button issue of semiconductors after President Trump gave Nvidia the go-ahead to sell its H200 chips to buyers in the world’s second-largest economy.

markets

ServiceNow strikes deal to buy cybersecurity firm Armis for $7.75 billion in cash

ServiceNow has agreed to acquire cybersecurity startup Armis for $7.75 billion in an all-cash deal, the largest purchase in the company's history.

That price tag is $750 million above what Bloomberg suggested was the top end of what Armis would cost just last week, and about $1.65 billion above what the company had been valued at in a November funding round.

Armis had been readying itself for an IPO, with many major investors looking to take a stake in the firm.

Instead, it’s now a key cog in the software platform company’s bid to lean on cybersecurity features to bolster its appeal to customers in a world in which the rise of AI adds to the potential threats of business disruptions and data breaches.

Per the press release:

As rapid AI adoption expands the attack surface for organizations, real-time visibility into vulnerabilities and actionable insights for what to fix first are critical to minimize risk and strengthen security posture. The acquisition of Armis will extend and enhance ServiceNow’s Security, Risk, and OT portfolios in critical and fast-growing areas of cybersecurity and drive increased AI adoption by strengthening trust across businesses’ connected environments.

markets

Novo Nordisk rallies after FDA weight loss pill approval

Novo Nordisk’s US-listed shares are up 7% in pre-market trading on Tuesday after the US Food and Drug Administration approved its Wegovy weight loss pill on Monday evening.

Now the first pill of its kind to receive approval from the regulator, Novo’s Wegovy pill is expected to launch in the US in early January 2026, and awaits the European Medicines Agency and other regulatory authorities’ approval after submitting for review in the second half of 2025, per the company’s press release. The 1.5 milligram starting dose of the pill will be sold at an introductory price of $149 a month.

“The pill is here. With today's approval of the Wegovy® pill, patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy® injection,” said Mike Doustdar, president and CEO of Novo Nordisk.

The approval was based on Novo’s Oasis 4 trial, which found participants who took 25 milligram doses of Wegovy pills daily lost 16.6% of their body weight over a 64 week period.

The approval will give Novo — which lost more than 50% of its market cap this year after Eli Lilly took the crown in weekly US prescriptions for injectable weight-loss drugs with its product Zepbound — a first-mover advantage in the expanding market. Lilly, which is down some 1% in pre-market trading today, has said its own oral drug orforglipron could be approved by March 2026.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.